- Home
- RPTX vs WHWK Comparison
RPTX vs WHWK Comparison
Compare RPTX & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPTX | WHWK |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.4M | 95.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | RPTX | WHWK |
|---|---|---|
| Price | $2.18 | $2.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 193.7K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $11,870,000.00 | ★ $14,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.89 | $1.39 |
| 52 Week High | $4.07 | $3.81 |
Technical Indicators
Market Signals| Indicator | RPTX | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 60.56 | 57.64 |
| Support Level | $2.15 | $2.10 |
| Resistance Level | $2.24 | $2.59 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 57.35 | 79.03 |
Price Performance
Historical ComparisonAbout RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.